当前位置: 首页 > 师资队伍 > 教授 > 微生物学与免疫学系 > 正文
师资队伍

微生物学与免疫学系

张海红

日期:2020-08-11 点击数: 来源:


张海红


姓名: 张海红
职称: 教授
最高学位: 博士
电话: 13504403487
Email:
工作地点: 生命科学楼413室


研究方向: 肿瘤免疫治疗 肿瘤疫苗研究
教育经历:

1999.09-2003.07 吉林师范大学生命科学学院 本科

2003.09-2006.07 吉林大学生命科学学院   硕士 

2006.09-2009.07 吉林大学生命科学学院   博士

工作经历:

2009.07-2012.09 吉林大学生命科学学院艾滋病疫苗国家工程实验室 讲师

2012.10-2019.12 吉林大学生命科学学院艾滋病疫苗国家工程实验室 副教授

2019.09-2020.09 美国匹兹堡大学医学院 访问学者 

2020.01-现在 吉林大学生命科学学院艾滋病疫苗国家工程实验室 教授

荣誉称号: 第五届吉林省大学生生命科学创新实验大赛中,荣获指导教师二等奖。

研究成果:

代表性文章

1. Fei Geng, Ling Dong, Xin Bao, Qianqian Guo, Jie Guo, Yi Zhou, Bin Yu, Hui Wu, Jiaxin Wu, Haihong Zhang*, Xianghui Yu*, and Wei Kong, CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer. Molecular Therapy-Oncolytics, accepted.

2. Dong L, Feng M, Qiao Y, Liu C, Zhou Y, Xing S, Zhang K, Cai Z, Wu H, Wu J, Yu X, Zhang H*, Kong W*. Preclinical Safety and Biodistribution in Mice Following Single-Dose Intramuscular Inoculation of Tumor DNA Vaccine by Electroporation. Hum Gene Ther. 2022 Jul; 33 (13-14):757-764.

3. Liu C, Cong X, Wang Y, Guo Q, Xie Y, Geng F, Guo J, Dong L, Zhou Y, Wu H, Yu B, Wu J, Zhang H*, Yu X*, Kong W. Fast DNA Vaccination Strategy Elicits a Stronger Immune Response Dependent on CD8+CD11c+ Cell Accumulation. Front Oncol. 2021 Dec 7; 11 : 752444.  

4. Qianqian Guo, Lizheng Wang, Ping Xu, Fei Geng, Jie Guo, Ling Dong, Xin Bao, Yi Zhou, Mengfan Feng, Jiaxin Wu, Hui Wu, Bin Yu, Haihong Zhang*, Xianghui Yu, Wei Kong*. Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse. Oncoimmunology. 2020 Nov 9; 9 (1) : 1841392.

5. Fei Geng, Xin Bao, Ling Dong, Qian-Qian Guo, Jie Guo, Yu Xie, Yi Zhou, Bin Yu, Hui Wu, Jia-Xin Wu, Hai-Hong Zhang*, Xiang-Hui Yu*, Wei Kong. Doxorubicin Pretreatment Enhances FAPα/survivin Co-Targeting DNA Vaccine Anti-Tumor Activity Primarily Through Decreasing Peripheral MDSCs in the 4T1 Murine Breast Cancer Model.Oncoimmunology. 2020 Apr 16;9(1):1747350. 

6. Fei Geng, Jie Guo, Qian-Qian Guo, Yu Xie, Ling Dong, Yi Zhou, Chen-Lu Liu, Bin Yu, Hui Wu, Jia-Xin Wu, Hai-Hong Zhang*, Wei Kong*, Xiang-Hui Yu*. A DNA vaccine expressing an optimized secreted FAPα induces enhanced anti-tumor activity by altering the tumor microenvironment in a murine model of breast cancer. Vaccine 2019,37(31):4382-4391.

7. Chenlu Liu, Zhenzhen Lu, Yu Xie, Qianqian Guo, Fei Geng, Bo Sun, Hui Wu, Bin Yu, Jiaxin Wu, Xianghui Yu, Wei Kong, Haihong Zhang*, Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect. Immunology letter2018 Jun 9; 200:33-42.

8. Chenlu Liu, Yu Xie, Bo Sun, Fei Geng, Fangfang Zhang, Qianqian Guo, Hui Wu, Bin Yu, Jiaxin Wu, Xianghui Yu, Wei Kong, Haihong Zhang*.MUC1- and survivin - based DNA vaccine combining immunoadjuvants CpG and interleukin 2 in  bicistronic expression plasmid generates specific immune responses and anti-tumor effects in a murine colorectal carcinoma modelScand J Immunol. 2018 Feb; 87 (2):63-72.

9. Qiu Xia, Fei Geng, Fang-Fang Zhang, Chen-Lu Liu, Ping Xu, Zhen-Zhen Lu, Yu Xie, Hui WuBo Sun, Wei Kong, Xiang-Hui Yu, Hai-Hong Zhang*. Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein α-based DNA vaccine in tumor-bearing mice with murine breast carcinoma.Immunopharmacol Immunotoxicol. 2017 Feb;39(1):37-44.

10. Qiu Xia, Fang-Fang Zhang, Fei Geng, Chen-Lu Liu, Yu-Qian Wang, Ping Xu, Zhen-Zhen Lu, Yu Xie, Hui Wu, Yan Chen, Yong Zhang, Wei Kong, Xiang-Hui Yu, Hai-Hong Zhang*, Improvement of anti-tumor immunity of fibroblast activation protein a based vaccines by combination with cyclophosphamide in a murine model of breast cancer.Cellular Immunology. 2016 Dec; 310:89-98.

11. Qiu Xia, Fei Geng, Fang-Fang Zhang, Chen-Lu Liu, Ping Xu, Zhen-Zhen Lu, Bin Yu, Hui Wu, Jia-Xin Wu, Hai-Hong Zhang*, Wei Kong, Xiang-Hui Yu.Enhancement of FAPα-targeted immunotherapy and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice. Vaccine. 2016 Aug 31; 34(38): 4526-35.

12. Haihong Zhang, Chenlu Liu, Qiu Xia, Zhenzhen Lu, Ping Xu, Fangfang Zhang, Fei Geng, Hui Wu, Bin Yu, Jiaxin Wu, Xianghui Yu*, and Wei Kong*MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model. Vaccine. 2016 May 23; 34(24):2648-55.

13. Qiu Xia, Fang‑Fang Zhang, Fei Geng, Chen‑Lu Liu, Ping Xu, Zhen‑Zhen Lu, Bin Yu, Hui Wu, Jia‑Xin Wu, Hai‑Hong Zhang*, Wei Kong, Xiang‑Hui Yu. Anti‑tumor effects of DNA vaccine targeting human fibroblast activation protein α by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model.Cancer Immunology Immunotherapy. 2016 May; 65(5):613-24. doi: 10.1007/s00262-016-1827-4.

14. YuQian Wang, Chenlu Liu, Qiu Xia, Wang Peng, Bo Li, Zhenzhen Lu, Jiaxi Sun, Hui Wu, Bin Yu, Jiaxin Wu, Xianghui Yu, Wei Kong, HaiHong Zhang* and Xianling Cong*. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs. Oncol Rep.2014 Mar;31(3):1437-44.

15. Hui Wu#, Haihong Zhang#, Yue Hu, Qiu Xia, Chenlu Liu, Yingnan Li, Bin Yu, Tiejun Gu, Xizhen Zhang, Xianghui Yu,* and Wei Kong,*.Sphere Formation Assay is Not an Effective Method for Cancer Stem Cell Derivation and Characterization from the Caco-2 Colorectal Cell Line. Curr Stem Cell Res Ther. 2014 Mar; 9(2):82-8.

16. Hui Wu,† Haihong Zhang,† Peng Wang, Zhuo Mao, Li Feng, Yuqian Wang, Chenlu Liu, Qiu Xia, Bo Li, Heya Zhao, Yan Chen, Jiaxin Wu, Wei Kong,* Xianghui Yu*Short-Form CDYLb but not long-form CDYLa functions cooperatively with histone methyltransferase G9a in hepatocellular carcinomas. Genes Chromosomes Cancer. 2013 Jul; 52(7):644-55.

17. Yu-Qian Wang1, Hai-Hong Zhang1, Chen-Lu Liu, Hui Wu, Peng Wang, Qiu Xia, Li-Xing Zhang, Bo Li, Jia-Xin Wu, Bin Yu, Tie-Jun Gu, Xiang-Hui Yu*, Wei Kong*. Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model. International Immunopharmacology.2013 Apr 25; 17(1):9-17.

18. Yu-Qian Wang&, Hai-Hong Zhang&, Chen-Lu Liu, Qiu Xia, Hui Wu, Xiang-Hui Yu*, Wei Kong*. Correlation between auto-antibodies to survivin and MUC1 VNTR in colorectal cancer. Asian Pacific Journal of Cancer Prevention. 2012, 13: 5557-62.

19. Haihong Zhang, Yuqian Wang, Chenlu Liu, Lixing Zhang, Qiu Xia, Yong Zhang, Jiaxin Wu, Chunlai Jiang, Yan Chen, Yongge Wu, Xiao Zha, Xianghui Yu* and Wei Kong*. DNA and Adenovirus Tumor Vaccine Expressing Truncated Survivin Generates Specific Immune Responses and Antitumor Effects in a Murine Melanoma Model. Cancer Immunology Immunotherapy. 2012,61:1857–1867

20. ZHANG Haihong, ZHANG Shuzi, YU Xianghui, KONG Wei*. Construction and Expression of Human Survivin and Preparation of Its Polyclonal Antibody. Chemical Research In Chinese Universities. 2008 24(6), 767-770.

主持、参与或执行的科研项目:     

1. “十三五”国家科技重大专项,2018ZX09301050-003、创新肿瘤治疗性疫苗的研发、2018/06-2020/12183.85 万元、主持;

2. 吉林省科技处,20160519018JH、吉林省新型肿瘤疫苗研究创新团队、2016.01-2018.1220万元、参与、在研;

3. “十二五”国家科技重大专项,2014ZX09304314-001、以survivinMUC1为靶点重组腺病毒载体肿瘤治疗性疫苗的临床前研究、164.47万、执行、已结题;

4. 国家自然基金青年项目,31300765、以 MUC1 VNTRsurvivinFAP-α为靶点的自组装纳米载体基因疫苗抗肿瘤作用机制研究、2014/01-2016/1223万元、主持、已结题;

5. 长春百克生物科技股份公司、肿瘤治疗性疫苗的研究、2012-2019120万元、主持、在研,

6. 吉林省科技发展计划,20130522006JH、双基因自组装纳米载体肿瘤疫苗研究、2013.01-2015.123万元、主持、已结题;

7. 教育部新教师基金,20120061120025、针对肿瘤微环境及肿瘤细胞的三基因肿瘤疫苗作用机制研究、2013.01-201 5.124万元、主持、已结题;

8. 吉林省产业技术研究与开发专项项目,2013C014-3、肺癌早期基因诊断技术的研究与开发、2013/01 - 2014/1210万元、参与、已结题;

9. 吉林大学基本科研业务费,450060323260、以 survivinMUC1 VNTRs 为靶点的肿瘤基因疫苗免疫佐剂的效果研究、2011/01-2012/122万元、主持、已结题;

10. 吉林大学交叉学科项目,200903255、以 survivinMUC1 VNTRs 为靶点的肿瘤基因疫苗异源prime - boost免疫策略的研究、2009/12-2011/015万元、主持、已结题。

专利

1. FAPαsurvivin为基础的DNA及其在制备肿瘤疫苗中的应用(专利申请号:201911237825.4 ) 发明人:张海红;于湘晖;孔维;耿飞;郭杰。

2. 以序列优化的分泌形式的FAPα为基础的肿瘤DNA疫苗的应用(专利申请号:201910498855.4),发明人:张海红;于湘晖;孔维;耿飞;郭杰

3. FAPαCTL表位肽为基础的肽类疫苗和微基因疫苗的应用(专利号:ZL201711060548.5, 发明人:张海红、于湘晖、孔维、张芳芳、刘晨露、徐平、耿飞、谢雨、郭倩倩、陆臻桢

4. 以成纤维激活蛋白α为靶点的肿瘤DNA疫苗及病毒载体疫苗(专利号: ZL201610363126.4),发明人:张海红 于湘晖 孔维 夏秋 耿飞,

5. 以粘蛋白1和生存素为靶点的肿瘤DNA疫苗和病毒载体疫苗(专利号:ZL200910252427.x,发明人:孔维;张海红;于湘晖;于永慧

6. 以粘蛋白1和生存素为靶点的肿瘤基因工程疫苗(专利号:ZL201110086366.1),发明人:孔维 张海红 于湘晖 于永慧 王玉倩 张丽星

7. 以粘蛋白1和生存素为靶点的肿瘤DNA疫苗及病毒载体疫苗-分案(申请号:ZL201410189139.5),发明人:孔维;张海红;于湘晖;于永慧

8. 重组疫苗及其应用(申请号201711190257 .8,申请日:2017.11.24),发明人:孔维,张海红,于湘晖,陆臻桢,刘晨露,徐萍,耿飞,张芳芳,谢雨,郭倩倩

9. 国际专利名称:重组疫苗及其应用(申请号PCTCN2018116393,申请日:20181120 优先权日:2017.11.24),发明人:孔维,张海红,于湘晖,陆臻桢,刘晨露,徐萍,耿飞,张芳芳,谢雨,郭倩倩